Most commercial red light therapy buyers ask the same question during evaluation: where is the science. The answer is that photobiomodulation, the technical name for red and near-infrared light therapy at therapeutic wavelengths, is one of the most published areas in modern wellness research. PubMed indexes more than 7,000 peer-reviewed studies on the topic, with new papers appearing every week.

For a commercial operator, the volume is the problem, not the solution. Most published research is animal model or in vitro work that does not translate directly to commercial bed protocols. Some human trials are small and underpowered. A few are well-designed randomized controlled trials. Knowing which is which is the difference between marketing copy that survives FDA scrutiny and marketing copy that does not.

This article highlights five studies that every commercial operator should know by name. Each one is peer-reviewed, citable, and represents a distinct piece of the evidence base: mechanism, dose response, wavelength selection, application, and the limits of current research. We summarize each study’s design, primary finding, and the responsible way to reference it in client conversations and marketing copy. We also note what each study does not prove, because that distinction matters for FDA registered manufacturers and the operators who buy from them.

Why does the published research base matter for a commercial operator?

The research base matters for three operational reasons.

First, it sets the boundary for client conversations. An operator who cites peer-reviewed evidence accurately builds trust. An operator who overstates findings creates exposure. The FTC has issued warning letters to wellness businesses that claim therapeutic benefits beyond their device’s regulatory scope (FTC Health Products Compliance Guidance). Knowing what the evidence supports, and what it does not, is the cleanest defense.

Second, it informs equipment selection. Studies use specific wavelengths, irradiance levels, and dose ranges. Equipment that operates outside those parameters delivers something different from what the studies tested. A bed marketed at 850 nanometers behaves differently from one marketed at 660 nanometers, and the published evidence for each wavelength is not interchangeable.

Third, it stabilizes pricing conversations. A client asking why a 15 minute session costs $50 deserves more than a marketing claim. Citing a specific dose response study and explaining why session length is calibrated to that evidence shifts the conversation from “trust me” to “here is the evidence.” That shift matters for membership renewals.

The five studies below are starting points, not the entire literature. An operator who reads these five and understands them is better prepared than 95 percent of the market.

Study 1: What did Karu’s mechanism research establish about cytochrome c oxidase?

Citation: Karu, T. (1999). Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Journal of Photochemistry and Photobiology B: Biology, 49(1), 1 to 17.

Study type: Review paper synthesizing mechanism research

What it established: Tiina Karu’s foundational work identified cytochrome c oxidase, the terminal enzyme in the mitochondrial electron transport chain, as a primary photoacceptor for red and near-infrared light. The paper proposed that photon absorption by cytochrome c oxidase increases ATP production and modulates downstream cellular signaling. This mechanism is now the most widely cited explanation for the cellular effects of photobiomodulation (Journal of Photochemistry and Photobiology B).

What it does not prove: The Karu mechanism is well-supported in cell culture and in vitro work. It does not prove any specific clinical outcome at the whole-body level. The path from “ATP production increases at the cellular level” to “this client’s joint pain improves” requires additional clinical evidence for each application.

How an operator should reference it: “Published mechanism research suggests that red and near-infrared wavelengths interact with cytochrome c oxidase to support cellular energy production.” This is accurate, attributed to research, and stays within ILY scope.

Study 2: What did the Huang dose response review reveal about the biphasic curve?

Citation: Huang, Y. Y., Chen, A. C., Carroll, J. D., & Hamblin, M. R. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358 to 383.

Study type: Review paper analyzing dose response patterns across the published literature

What it established: The Huang paper documented what photobiomodulation researchers call the biphasic dose response. Across multiple published studies, biological response increased with light dose up to a peak, then decreased as dose continued to increase. More light was not better past the inflection point. The paper established that effective photobiomodulation requires a calibrated dose, not a maximum dose (Dose-Response journal).

What it does not prove: The biphasic curve is well-documented in mechanism studies and selected clinical trials. The exact peak dose for each application, tissue type, and individual is not established. Operators should treat published dose ranges as informed starting points, not precise prescriptions.

Why it matters for commercial protocols: Session length, irradiance, and frequency all factor into total dose. A high irradiance bed at 65 milliwatts per square centimeter delivers a calibrated dose in a 12 to 20 minute session. A low irradiance device may require a longer session to deliver the same dose, and may still fall short of the documented effective range.

Study 3: What did the Hamblin near-infrared review establish about tissue penetration?

Citation: Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337 to 361.

Study type: Review paper covering mechanism, wavelength selection, and inflammation research

What it established: Hamblin synthesized published evidence on tissue penetration depth for red and near-infrared wavelengths. Red light at 630 to 670 nanometers is absorbed primarily by skin and superficial tissue. Near-infrared light at 810 to 850 nanometers penetrates several millimeters deeper into muscle and connective tissue. The paper also reviewed published evidence on photobiomodulation effects on inflammatory markers in cell culture and animal models (AIMS Biophysics).

What it does not prove: Penetration depth is reasonably well-established in tissue optics. The paper does not prove that deeper penetration always produces better clinical outcomes. The right wavelength depends on the target tissue and the application, not a single “deeper is better” rule.

How an operator should reference it: “Published research on photobiomodulation indicates that 630 to 670 nanometer wavelengths interact primarily with superficial tissue, while 810 to 850 nanometer wavelengths penetrate to deeper muscle and connective tissue.” Accurate, sourced, and useful for explaining why a commercial bed combines both wavelength ranges.

Study 4: What did the Ferraresi muscle recovery research show?

Citation: Ferraresi, C., Huang, Y. Y., & Hamblin, M. R. (2016). Photobiomodulation in human muscle tissue: an advantage in sports performance? Journal of Biophotonics, 9(11 to 12), 1273 to 1299.

Study type: Review paper synthesizing muscle and athletic performance research

What it established: The Ferraresi paper reviewed dozens of published studies on photobiomodulation applied to human muscle tissue before, during, and after exercise. The synthesized findings included evidence for reduced post-exercise inflammation markers, faster recovery of muscle force, and reduced delayed onset muscle soreness in selected studies. The paper organized the evidence by study design, dose, and application timing (Journal of Biophotonics).

What it does not prove: Athletic recovery applications have a growing evidence base, but the studies vary in quality. Some are small open label studies. Others are well-designed randomized controlled trials. The Ferraresi review acknowledges this variation and does not claim that photobiomodulation is universally effective for athletic recovery.

Why it matters for commercial operators: This is the citation that supports recovery and athletic positioning, when used responsibly. An operator can reference the published evidence on muscle recovery without claiming that any specific commercial unit treats injuries or accelerates healing. The distinction between “published research suggests” and “this device treats” is the line between compliant and non-compliant marketing.

Study 5: What did the Cochrane review conclude about the limits of current evidence?

Citation: Brosseau, L., Robinson, V., Wells, G., et al. (2005). Low level laser therapy (Classes I, II and III) for treating osteoarthritis. Cochrane Database of Systematic Reviews, (2), CD002046.

Study type: Cochrane systematic review

What it established: Cochrane reviews are considered the highest tier of evidence synthesis in medical research. The 2005 review on low level laser therapy for osteoarthritis examined published randomized controlled trials and concluded that the evidence at the time was mixed. Some studies showed benefit, others did not, and methodological quality varied. The review called for higher-quality randomized controlled trials before drawing definitive conclusions (Cochrane Library).

What it does not prove: The Cochrane review does not say photobiomodulation does not work. It says, accurately, that the evidence base is incomplete and inconsistent. Subsequent reviews and trials have continued to add evidence on both sides.

Why every operator should know this study: This is the citation that prevents overclaiming. An operator who can quote a Cochrane review and explain that the evidence base is still developing builds more credibility than one who cherry picks favorable studies. The Cochrane review is the antidote to marketing copy that overstates the science.

How should an operator reference research without making product claims?

This is the practical question that determines whether marketing copy is compliant or exposed.

The clean structure follows three rules.

Rule one: attribute findings to research, not to the device. “Published research suggests that photobiomodulation may support cellular energy production” is compliant. “Our red light therapy bed boosts cellular energy” is not. The first describes peer-reviewed evidence. The second is a product claim outside ILY scope.

Rule two: cite specific studies with full URLs. A reference to “studies show” or “research suggests” without a citation is weak both rhetorically and legally. A specific citation with author, year, journal, and URL is verifiable, defensible, and demonstrates earned authority.

Rule three: state the limit of the evidence. When a study supports a finding in muscle tissue, do not extend the claim to whole-body benefits. When a study is small, say it is small. The operator who acknowledges limits is more credible than the one who hides them.